Clinical Cancer Drugs


Giulio Francia
The University of Texas
El Paso, TX

Personal Subscription
Become EABM
Become Reviewer
Call for Editor

Complex 3D Models to Study Drug Targeting of Invadopodia

Volume:1   Issue: 2
Pp: 85-89
Njainday Pulo Jobe, Daniel Rosel, Ondrej Tolde, Jan Kosla and Jan Brabek
DOI: 10.2174/2212697X113016660003
Published on: 28 May, 2014

Preclinical Models to Study Breast Cancer open access plus

Volume:1   Issue: 2
Pp: 90-99
Cynthia M. Rodriguez, Paloma Valenzuela, Natzidielly Lerma and Giulio Francia
DOI: 10.2174/2212697X113026660005
Published on: 28 May, 2014

The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs

Volume:1   Issue: 2
Pp: 100-115
Antonello Di Paolo, Guido Bocci and Romano Danesi
DOI: 10.2174/2212697X01666131218234741
Published on: 28 May, 2014

Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy open access plus

Volume:1   Issue: 2
Pp: 116-126
Annabelle Chow, Giulio Francia, Andrew Kouri, Christina Lee, John M. Ebos, Robert S. Kerbel and Urban Emmenegger
DOI: 10.2174/2212697X01666131218235200
Published on: 28 May, 2014

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

Volume:1   Issue: 2
Pp: 127-148
Manikanta Swamy Murahari and Mayur C. Yergeri
DOI: 10.2174/2212697X01666140128002849
Published on: 28 May, 2014

Acknowledgements to Reviewers promotion: free to download

Volume:1   Issue: 2
Pp: 149-149

DOI: 10.2174/2212697X0102140529153231
Published on: 28 May, 2014